Biolife Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:4em;'>BS</div>
BLFS -- USA Stock  

USD 33.70  0.11  0.33%

Biolife Solutions Working Capital is relatively stable at the moment as compared to the past year. Biolife Solutions reported last year Working Capital of 18.91 Million. As of 03/21/2021, Asset Turnover is likely to grow to 0.37, while Earnings before Tax are likely to drop (3.1 M). As many baby boomers are still indifferent towards healthcare space, it makes sense to sum up Biolife Solutions. We will evaluate why we are still optimistic in anticipation of a recovery. In this post, I will also go over a few different drivers affecting Biolife Solutions' products and services, and explain how it may impact Biolife Solutions retail investors.
Published over three weeks ago
View all stories for Biolife Solutions | View All Stories
Is Biolife Solutions (NASDAQ:BLFS) turning things around?
The company's average rating is Buy from 7 analysts.
Biolife Solutions advice module can be used to check and cross-verify current investment recommendation provided by analysts analyzing the company's potential to grow using all of fundamental, technical, data market data available at the time.

How important is Biolife Solutions's Liquidity

Biolife Solutions financial leverage refers to using borrowed capital as a funding source to finance Biolife Solutions ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Biolife Solutions financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Biolife Solutions's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Biolife Solutions, but it might be worth checking our own buy vs. sell analysis

What did Biolife Solutions file with SEC?

The SEC filings are financial statements or other formal documents of Biolife Solutions that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.
Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Biolife shareholders may or may not be submitted as SEC does not always require it.
7th of April 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
17th of February 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
1st of December 2020
Other Events
View
27th of November 2020
Unclassified Corporate Event
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Biolife shareholders may or may not be submitted as SEC does not always require it.

What is driving Biolife Solutions Investor Appetite?

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biolife Solutions has an asset utilization ratio of 336.79 percent. This connotes that the company is making $3.37 for each dollar of assets. An increasing asset utilization means that Biolife Solutions is more efficient with each dollar of assets it utilizes for everyday operations.
 2018 2019 2020 2021 (projected)
Current Assets37.56 M24.11 M27.73 M29.92 M
Total Assets45.47 M92.82 M106.74 M115.17 M

Will Biolife Solutions growth be viable after the spike?

Latest variance is at 13.3. Biolife Solutions exhibits very low volatility with skewness of 0.21 and kurtosis of -0.13. However, we advise investors to further study Biolife Solutions technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biolife Solutions' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biolife Solutions' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Bottom Line On Biolife Solutions

While some firms within the medical instruments & supplies industry are still a little expensive, even after the recent corrections, Biolife Solutions may offer a potential longer-term growth to retail investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Biolife nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biolife Solutions.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Biolife Solutions. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com